There were 689 press releases posted in the last 24 hours and 167,013 in the last 365 days.

OXIDIEN PHARMACEUTICALS TO PRESENT AT THE 2020 BIO CEO & INVESTOR CONFERENCE

GAINESVILLE, FL, US, February 6, 2020 /EINPresswire.com/ -- Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, today announced that it will present a corporate overview at the BIO CEO & Investor Conference, being held at the Marriott Marquis Times Square in New York City.

Presentation Details:

Date: Monday, February 10th, 2020
Time: 3:45 p.m. (ET)
Location: Wilder Room

ABOUT OXIDIEN PHARMACEUTICALS, LLC
Oxidien Pharmaceuticals is a clinical stage biopharmaceutical company addressing a large unmet need in kidney disease. The company is focused on treating secondary hyperoxaluria using novel oral enzymatic approaches. Oxidien has a strong intellectual property position with patents pending world-wide. The leadership team has a proven track record of successful product development, regulatory approval, and with operating, growing and exiting healthcare businesses. Oxidien Pharmaceuticals is located in UF Innovate the Hub - a world-recognized leader in biotechnology business incubation affiliated with one of the nation’s leading research institutions, the University of Florida. For additional information on UF Innovate the Hub please visit http://innovate.research.ufl.edu/. For additional information on Oxidien please visit www.oxidien.com.

Helena Cowley
Oxidien Pharmaceuticals
+1 352-672-5320
email us here
Visit us on social media:
Twitter
LinkedIn


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.